Kenvue (NYSE:KVUE - Free Report) had its price objective increased by Piper Sandler from $24.00 to $27.00 in a research note published on Monday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.
A number of other equities research analysts have also commented on KVUE. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Citigroup dropped their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. Finally, Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and a consensus target price of $23.08.
Read Our Latest Analysis on Kenvue
Kenvue Trading Up 1.9 %
NYSE:KVUE traded up $0.44 on Monday, reaching $23.58. The company's stock had a trading volume of 30,980,726 shares, compared to its average volume of 14,602,373. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46. The business's 50-day moving average price is $21.42 and its two-hundred day moving average price is $22.24. The firm has a market cap of $45.07 billion, a PE ratio of 44.49, a PEG ratio of 2.62 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is presently 154.72%.
Institutional Investors Weigh In On Kenvue
A number of institutional investors and hedge funds have recently modified their holdings of KVUE. Grove Bank & Trust increased its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. raised its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue during the 3rd quarter worth about $35,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after acquiring an additional 777 shares during the period. 97.64% of the stock is owned by institutional investors.
About Kenvue
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
